β-thalassaemic mouse model given BB305 LVV-transduced mouse BMCs: correction of the β-thalassaemic phenotype
“were evaluated in of pivotal pharmacology studies in the β-thalassaemic murine animal model. Results showed that treatment of thalassaemic mice resulted in the correction of the β-thalassaemic phenotype.”
Product is human autologous thalassaemic CD34+ cells, so surrogate test articles were used
“Considering the nature of the final drug product (human autologous thalassaemic CD34+ haematopoietic stem cells transduced with the BB305 lentiviral vector), the test articles used during non-clinical studies were surrogates”
Four combined in vivo studies, though not fully GLP, allowed assessment of primary pharmacodynamics and toxicity
“Even if not fully compliant to GLP principles, these four in vivo combined studies allowed the assessment of both primary pharmacodynamics and toxicity.”
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function